<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395365</url>
  </required_header>
  <id_info>
    <org_study_id>17/0894</org_study_id>
    <nct_id>NCT04395365</nct_id>
  </id_info>
  <brief_title>Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis</brief_title>
  <acronym>ASEPTIC</acronym>
  <official_title>Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, interventional, double-blind, placebo-controlled, parallel-arm, phase 3,
      randomised controlled trial to evaluate the use of co-trimoxazole as primary prophylaxis for
      spontaneous bacterial peritonitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous bacterial peritonitis</measure>
    <time_frame>24 months following randomisation</time_frame>
    <description>Time to first incidence of spontaneous bacterial peritonitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous bacterial peritonitis infection</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of spontaneous bacterial peritonitis infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Hospital admission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C. difficile-associated diarrhoea</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of C. difficile-associated diarrhoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections other than spontaneous bacterial peritonitis with hospital admission</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of infections other than spontaneous bacterial peritonitis with hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of renal dysfunction with creatinine &gt;133 μmol/L (1.5mg/dL) at any point during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplantation</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver disease assessed by increase in MELD score</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Progression of liver disease assessed by increase in MELD score between baseline and end of trial follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and treatment-related adverse events</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Safety and treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Treatment adherence (assessed by MARS questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Health-related quality of life assessed using EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and social care</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Health and social care resource use assessed using Hospital Episode Statistics (HES) database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean incremental cost per quality adjusted life year gained (QALY)</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Mean incremental cost per quality adjusted life year gained (QALY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of resolution of ascites with diuretic treatment not required for 6 months</measure>
    <time_frame>Up to 24 months from randomisation</time_frame>
    <description>Incidence of resolution of ascites with diuretic treatment not required for 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Co-trimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 960mg capsule oral tablet, to be taken daily for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-Trimoxazole 960Mg Dispersible Tablet</intervention_name>
    <description>Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis</description>
    <arm_group_label>Co-trimoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with liver cirrhosis and ascites with ascitic fluid protein count &lt;2.0 g/dL
             (from sample taken within &lt;12 weeks prior to randomisation)

          2. Patients with ascitic polymorphonuclear count &lt;250 cells/mm3 and negative microbial
             culture at 5 days (on the last sample sent within &lt;12 weeks prior to randomisation)

          3. Patient at least 18 years of age

          4. Documented informed consent to participate

        Exclusion Criteria:

          1. Patients with previous Spontaneous Bacterial Peritonitis (SBP)

          2. Patients receiving palliative care with an expected life expectancy of &lt;8 weeks

          3. Allergic to co-trimoxazole, trimethoprim or sulphonamides

          4. Pregnant or lactating mothers

          5. Patient enrolled in a clinical trial of investigational medicinal products (IMPs) that
             would impact on their participation in the study

          6. Patients with persistent hyperkalaemia (&gt;6.5 mmol/L) related to pre-existing kidney
             disease with reduction not possible

          7. Patients receiving antibiotic prophylaxis (except for rifaximin)

          8. Patients with long-term ascites drains

          9. Women of child bearing potential and males with a partner of child bearing potential
             without effective contraception for the duration of trial treatment

         10. Patients with pathological blood count changes (granulocytopenia, megaloblastic
             anaemia)

         11. Severe thrombocytopenia with a platelet count &lt;30 x109 /L

         12. Patients with severe renal impairment, with eGFR &lt;15 ml/min

         13. Patients with skin conditions: exudative erythema multiform, Stevens-Johnson syndrome,
             toxic epidermal necrolysis and drug eruption with eosinophilia and systemic symptoms

         14. Patients with congenital conditions: congenital glucose-6-Phosphate dehydrogenase
             deficiency of the erythrocytes, haemoglobin anomalies such as Hb Köln and Hb Zürich

         15. Patients with acute porphyria

         16. Any clinical condition which the investigator considers would make the patient
             unsuitable for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Gear</last_name>
    <phone>02076705748</phone>
    <email>david.gear.16@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marisa Chau</last_name>
    <email>m.chau@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Free hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alistair O'Brien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

